Indeed, the novel anti-cancer compound, NEO212, was recently shown to induce the lytic form of EBV infection in NPC cell lines in vitro via a CHOP-dependent mechanism [43]. The gene discussed is DDIT3; the disease is nasopharyngeal carcinoma.